GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BSP:GILD34) » Definitions » Net Income

Gilead Sciences (BSP:GILD34) Net Income : R$2,075 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Gilead Sciences Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Gilead Sciences's Net Income for the three months ended in Mar. 2024 was R$-20,766 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was R$2,075 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Gilead Sciences's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was R$-8.33.


Gilead Sciences Net Income Historical Data

The historical data trend for Gilead Sciences's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Net Income Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22,106.84 632.80 35,201.75 24,086.88 27,757.37

Gilead Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,260.69 5,072.12 10,766.37 7,001.81 -20,765.77

Gilead Sciences Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Gilead Sciences's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=33607.728+-6110.051+0+259.69
=27,757

Gilead Sciences's Net Income for the quarter that ended in Mar. 2024 is calculated as

Net Income(Q: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-22339.383+1568.637+0+4.9800000000032
=-20,766

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$2,075 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gilead Sciences  (BSP:GILD34) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Gilead Sciences's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Gilead Sciences Net Income Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (BSP:GILD34) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (BSP:GILD34) Headlines

No Headlines